Gyungah Jun

Associate Professor at Biomedical Genetics Section

Dr. Gyungah Jun
  • Title Associate Professor at Biomedical Genetics Section
  • Office 72 E Concord St, Boston, MA 02118
  • Phone 617-358-3581
  • Education • Ph.D. Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, OH
    • M.C.I.S. Computer and Information Science, Cleveland State University, Cleveland, OH
    • M.S. Microbiology and Immunology, Seoul National University, Seoul, South Korea
    • B.A. Agricultural Biology, Korea University, Seoul, South Korea

Dr. Jun is Associate Professor, Biomedical Genetics Section, Department of Medicine, Boston University School of Medicine. Dr. Jun has been involved in the Alzheimer’s Disease Genetics Consortium and the International Genomics of Alzheimer’s Project to identify AD risk genes within APOE genotype subgroups and across multi-ethnic populations. Dr. Jun previously worked at an industry position as a Director and Head of Neurogenetics and Integrated Genomics for Andover Innovative Medicines (AiM) Institute, Eisai Inc., where she was involved in genome-guided drug discovery projects in AD. After rejoining a full-time faculty position in 2018, she has contributed to establish large collaborated research programs. Dr. Jun is a founding member and one of four PIs for the Asian Cohort for Alzheimer’s Disease (ACAD) Consortium and Chairs in two workgroups, Data Management and Data Analysis. Dr. Jun is a Director at the Genome Guided Drug Discovery (GGDD) Core at the AI4AD consortium, which is a large coordinated national initiative for AD therapeutics will feature transformative Artificial Intelligence (AI) approaches using high throughput human big data. Dr. Jun is also a Steering Committee member at the large Framingham Heart Study Brain Aging Program (FHS-BAP), where she is leading genetic and molecular profiling using genomics and brain omics data in FHS to identify AD signatures from blood and brain. In addition, she has extended her interest in identification of APOE2 protective mechanisms against AD to establish a new cohort for prevention and treatment trials to target APOE for AD therapeutics.

Scientific Appointments

  • 2020-present Associate Director, Genetic and Molecular Profiling Core at Boston University Alzheimer’s Disease Research Center (ADRC)
  • 2020-present Director, Genome Guided Drug Discovery Core at AI4AD
  • 2020-present Chairs of Data Management and Analysis Workgroup, Asian Cohort for Alzheimer’s Disease (ACAD)
  • 2021-present Steering Committee Member, Multi-Ethnic Project, Alzheimer’s Disease Genetics Consortium (ADGC)

Other Employment

  • 2000-2006 Analyst Programmer II, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, OH
  • 2006-2009 Analyst Programmer III, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine, Cleveland, OH
  • 2015-2018 Director and Head, Neurogenetics and Integrated Genomics, Andover Innovative Medicines Institute, Eisai Inc., Andover, MA

Research Interests

  • Genetics and genomics for Alzheimer’s disease
  • Systems biology using multiple omics data
  • Genome guided precision medicine in Alzheimer’s disease
  • Machine learning and network based drug development and repurposing
  • Database and web interface development on Amazon

View all profiles